首页> 外文期刊>Pharmacology Research & Perspectives >Pharmacokinetics and pharmacodynamics of antibiotics in critically ill acute kidney injury patients
【24h】

Pharmacokinetics and pharmacodynamics of antibiotics in critically ill acute kidney injury patients

机译:危重症急性肾损伤患者的药代动力学和药效学

获取原文
           

摘要

Sepsis is the most common cause of death in critically ill patients and is associated with multiorgan failure, including acute kidney injury (AKI). This situation can require acute renal support and increase mortality. Therefore, it is essential to administer antimicrobials in doses that achieve adequate serum levels, avoiding both overdosing and drug toxicity as well as underdosing and the risk of antibiotic resistance and higher mortality. Currently, there are no validated guidelines on antibiotic dose adjustments in septic patients with AKI. The current recommendations were extrapolated from studies conducted in noncritical patients with end‐stage chronic kidney disease receiving chronic renal replacement therapy. This study aimed to review and discuss the complexity of this issue, considering several factors related to drug metabolism, the characteristics of critically ill patients, the properties of antimicrobial drugs and dialysis methods.
机译:脓毒症是重症患者最常见的死亡原因,并与多器官衰竭有关,包括急性肾损伤(AKI)。这种情况可能需要急性肾支持并增加死亡率。因此,必须以达到足够血清水平的剂量施用抗微生物剂,避免过量和药物毒性以及剂量不足以及抗生素耐药性和更高死亡率的风险。目前,尚无关于脓毒症AKI患者调整抗生素剂量的有效指南。当前的建议是从对接受慢性肾脏替代治疗的终末期慢性肾脏疾病的非危重患者进行的研究中推断得出的。这项研究旨在回顾和讨论此问题的复杂性,其中考虑了与药物代谢,危重病人的特征,抗菌药物的特性和透析方法有关的几个因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号